Novartis aims to transform patient care with life-changing, innovative therapies that provide patients with lasting freedom from diseases including a longer & healthier life for transplant and non-viral liver disease patients. Come to an industry leader with a heritage in transplantation where you will assist in driving the US Medical strategy for the development of products in transplant and non-viral liver diseases in the New Products Medical Unit.
The Executive Medical Director US New Products Transplant/Hepatology is responsible for establishing the US regional leadership on the development strategy for compounds in clinical development. This role will be instrumental in the externally focused aspect to engage in deep scientific exchange with leading researchers and be recognized as a multi-disciplinary expert by key institutions in the US, seeking insights to shape the US strategy including protocols, IDPs and pediatric plans.
Your responsibilities will include:
*Lead the US Medical strategy of development portfolio (phase II-III) *Co-Lead a US Matrix team across franchises (LPT) *Successfully create a bridge between GDD and NIBR and provide medical expertise to the commercial product development teams *Lead a team of CRMDs including recruiting, on-boarding, development, coaching, and performance management. *Develop an external engagement strategy to build sustainable strong relationships with external medical experts and investigators serving as the face of the therapeutic area lead for the pipeline, be able to engage medically and scientifically on eye level, be able to expand an existing strong network and build one in an area without an existing footprint. *Enable a positive team environment and interact with global, NIBR and TMO teams and lead by direct and indirect influence. *Define and deliver a clear, compelling and novel US strategy for pipeline products. *Partner across USCDMA to ensure early development programs are consistent with US standards of care and meet US ethical and regulatory standards by seeking external input and coordinating US consolidated input to Global on protocols, IDPs, Health Authority Briefing Books, etc. *Plan early and partner across USCDMA and with the TMO to proactively establish a clinical trial strategy to ensure timely trial initiation and completion.